In this study, we demonstrate the ability to repurpose sunitinib, a multi-tyrosine kinase inhibitor and first-line metastatic renal cell carcinoma (RCC) agent, to potentiate the immunotherapeutic efficacy of the oncolytic virus, reovirus. This novel therapeutic strategy not only improved tumor responses and overall survival in a murine model of RCC, but also, resulted in the generation of a systemic protective anti-tumor immune response. We validated our findings in a murine model of lung squamous cell carcinoma (SCC), highlighting the potential broad applicability of this treatment approach. Taken together, these results provide clear rationale to investigate this promising viroimmunotherapeutic strategy in early phase clinical trials for a broad range of tumor histologies.
Translational relevance
In this study, we demonstrate the ability to repurpose sunitinib, a multi-tyrosine kinase inhibitor and first-line metastatic renal cell carcinoma (RCC) agent, to potentiate the immunotherapeutic efficacy of the oncolytic virus, reovirus. This novel therapeutic strategy not only improved tumor responses and overall survival in a murine model of RCC, but also, resulted in the generation of a systemic protective anti-tumor immune response. We validated our findings in a murine model of lung squamous cell carcinoma (SCC), highlighting the potential broad applicability of this treatment approach. Taken together, these results provide clear rationale to investigate this promising viroimmunotherapeutic strategy in early phase clinical trials for a broad range of tumor histologies.
Introduction
Despite the improvements in progression free (PFS) and overall survival (OS) associated with the use of targeted therapy, metastatic renal cell carcinoma (mRCC) remains an incurable disease. With a five-year survival rate of less than 10% this malignancy remains a significant health issue [1] . As such, the need for the development of novel therapeutic strategies for this disease is obvious. Sunitinib, a multi-tyrosine kinase inhibitor targeting VEGFR, PDGFR, C-KIT, RET, CSF-1R and FLT-3 is currently a first line therapy for mRCC [2] . While this drug has historically been associated with potent anti-angiogenic activity, recent clinical studies have highlighted its immune modulatory effects. Indeed, following two cycles of oral sunitinib therapy at 50 mg daily for 4 weeks every 6 weeks, mRCC patients display an increase in the percentage of IFN-γ producing T-cells relative to treatment naive patients [3] . Moreover, the immune suppressive type-2 T-cell cytokine response and accumulation of T regulatory cells (Treg) and myeloid derived suppressor cells (MDSC) that are characteristic of mRCC patients is reversed following sunitinib therapy [3, 4] . Accordingly, this evidence has generated significant interest in targeting Tregs and MDSC with sunitinib to reverse the mRCC induced immunosuppressive microenvironment and enhance the anti-tumor immune response generated by immunotherapeutics [5] . The feasibility of this approach has been demonstrated in an immunocompetent syngeneic murine model of RCC (RENCA) in which the downregulation of MDSC and Treg by sunitinib enhanced intratumoral infiltration and activation of adoptively transferred CD8 + T-cells, leading to tumor regression [6] . Author Manuscript Published OnlineFirst on May 24, 2016; DOI: 10.1158/1078-0432.CCR- improve OS in mouse models of melanoma, hepatocellular carcinoma and colorectal metastasis in immunotherapeutic models, highlighting the efficacy and widespread utility of this approach against multiple histologies [7] [8] [9] .
In the current study, we investigated the ability of sunitinib to enhance the antitumor immune response generated by the dsRNA oncolytic reovirus. To date, reovirus is one of the most clinically advanced oncolytic viruses (OV), demonstrating modest efficacy in phase II clinical trials as a monotherapy and in combination with platinum and taxane based chemotherapy across multiple solid malignancies [10] [11] . Of the over 1,500 patients treated thus far with this agent, the maximum tolerated dose has not been reached, highlighting its tolerability and safety. As such, reovirus is one of the most promising OV currently being investigated in the clinic. Despite this however, early phase monotherapy clinical trials have failed to demonstrate appreciable clinical effectiveness in the form of objective and durable complete responses, highlighting the need to augment reovirus' therapeutic potency. Interestingly, in experimental murine models, reovirus administration is capable of priming innate and adaptive anti-tumor immune responses [12] [13] [14] . This anti-tumor immunity has not only been shown to contribute to reovirus' therapeutic efficacy, but has also been demonstrated to result in the generation of long-term tumor immunosurveillance [15] [16] [17] . Moreover, reovirusmediated anti-tumor immunity has been demonstrated clinically in a phase I trial of a single intra-prostatic injection of reovirus that involved 6 patients with localized prostate cancer [18] . In this study, despite the robust anti-viral neutralizing antibody response that was seen, a significant number of tumor infiltrating CD8 [19] . Hence, in addition to its direct oncolytic effects, reovirus is also a potent immunotherapeutic. While a considerable amount of literature supports reovirus' immunotherapeutic potential, most pre-clinical investigations have instead focused on improving the systemic delivery of the virus with immunosuppression or histology relevant cytotoxic chemotherapy, respectively [20, 21] . Grand Island, NY). All media was supplemented with 10% heat-inactivated fetal calf serum (FCS) (Invitrogen, Grand Island, NY). Cultures were free of antibiotics and negative for mycoplasma as determined by routine testing. Reovirus, Dearing strain serotype 3 was grown in L-929 cells then purified and tittered as previously described [18] . Sunitinib was purchased from Selleck chemicals (Houston, TX).
Cell Viability Assay. Cells were seeded at a density of 3 × 10 were then freeze-thawed 3 times and to quantify progeny production, supernatants were harvested and plaque titrated on monolayers of L-929 cells in semi-solid medium for 72 hours as previously described [18] .
Chemokine Expression Assay. Supernatants were harvested from RENCA cells infected with live (LV) or UV-inactivated reovirus (DV) for 12 or 24 hours in 6 well plates.
The multiplexing analysis was performed using the Luminex® 100 system (Luminex, Flow Cytometry. Flow Cytometry was performed as previously described [22] . Briefly, cell staining was done using FITC, Alexa Flour 488, PE, APC, PE-Cy7 or PerCP Cy5.5 conjugated rat monoclonal antibodies against CD4, CD8, Foxp3, CCR7, CD62L, CD11b and GR1 (Lyc6G+/Lyc6C)(BD Bioscience®). APC conjugated hamster IgG against Statistics. Statistical analysis was preformed utilizing Graph Pad version 6. Unpaired two-tailed t-tests and two-way ANOVA followed by Bonferroni Post Hoc tests were used to determine significance between experimental groups. Kaplan-Meier analysis together with log-rank sum test was utilized to determine significant for in vivo survival benefits. Reovirus has been demonstrated to initiate innate immune responses characterized by the production of pro-inflammatory cytokines including RANTES, MIP-1-α, MCP-1, KC, IP-10 and MIG across a variety of melanoma and prostate cancer cell lines in addition to its direct oncolytic effects [14, 17] . Based on these findings we characterized the ability of reovirus to stimulate production of these chemokines during infection of the murine RCC RENCA cell line. This cell line was studied to provide proof- 
The RENCA murine model of RCC is an established immunocompetent syngeneic model for studying novel therapeutics including immunotherapeutics against this disease preclinically [24] . This model was employed to investigate whether or not reovirus has therapeutic efficacy against RCC in vivo and determine the ability of sunitinib to augment this activity. Sunitinib dose response studies were conducted in vivo to determine the optimal dose to administer in combination with reovirus. A dose range of 20 to 60 mg/kg was chosen as it is clinically relevant and has previously been utilized in the RENCA model [6] . 
tumor volume (P < 0.001 by two-way ANOVA) ( Figure. 2A) . Tumor burden was not plotted beyond 18 days as considerable central necrosis in large tumors occurred limiting accurate measurement. Instead, overall survival was followed to establish longterm therapeutic efficacy. Kaplan-Meier analysis of two independent experiments with pooled results (8 mice overall) revealed an overall survival benefit (P < 0.05, log-rank sum test) for those mice receiving reovirus in combination with sunitinib versus either agent used as a monotherapy (Figure. 2B) . Death in all cases was a result of tumor progression as determined by tumor size greater than 2 centimeters in a single dimension or greater than 20 percent loss of body weight as per Animal Care institutional guidelines. Notably, animal body weights remained reasonably stable during treatment and no therapy specific toxicities were observed (Supplemental Figure. 3 ).
Sunitinib augments reovirus mediated anti-tumor immune response through reversal of tumor-induced immunosuppression.
As reovirus infection results in the production of pro-inflammatory cytokines and consequent priming of innate and adaptive immunity [14] [15] [16] [17] , the anti-tumor immune response generated by reovirus treatment of RCC in vivo was determined. Mice were treated as in Figure 2A This not only positions reovirus-sunitinib combination therapy as an attractive novel treatment strategy, but further supports the growing body of literature highlighting the benefit of harnessing the immune system to improve oncolytic virotherapy.
The conducted in vitro studies demonstrate the ability of reovirus to induce oncolysis against RCC, as has been described for multiple tumor histologies ( Figure. 
1A-C). Oncolysis of human RCC cell lines was seen within 48 hours of infection with all
ED 50 values being less than 40 MOI, which is comparable to that seen with other solid malignancies [18, [30] [31] [32] . Notably, the RENCA cell line demonstrated significantly greater in vitro sensitivity relative to human RCC cells, consistent with previous reports highlighting increased murine cell line sensitivity to reovirus [33] . While the precise mechanism for the enhanced sensitivity remains unknown, this observation suggested a direct oncolytic in vivo response could be achieved. As such, the established sensitivity of the RENCA cell line coupled with the observed production of pro-inflammatory cytokines known to be involved in the priming of reovirus mediated innate and adaptive immunity (RANTES, MIP-1α, MCP-1, KC, IP-10 and MIG) supported its use for in vivo investigation of reovirus immunotherapeutic efficacy against RCC as a model to establish pre-clinical proof-of-principle [14, 17] (Figure. 1D) . Moreover, these results also highlight that similar to infection of melanoma and prostate cancer cells, reovirus replication induces an inflammatory cell death response against RCC [14, 18] . 
The therapeutic utility of the in vitro studies was confirmed in vivo utilizing the RENCA immunocompetent murine model of RCC. Treatment of mice with reovirus and sunitinib resulted in a reduction in tumor burden relative to both PBS and DV controls ( Figure. 2A) . Furthermore, in those mice receiving reovirus and sunitinib, tumor specific CD8 + splenocytes could be isolated ( Figure. 3A-B) , highlighting the ability to generate a systemic adaptive anti-tumor immune response.
The combination of OV with relevant standard-of care treatments will likely be essential for their successful translation into clinical practice. The observation that the combination of sunitinib, a first-line mRCC therapeutic, with reovirus resulted in a significant regression in tumor burden and improved overall survival relative to either of these agents given as monotherapies, providing proof-of-principle to support the use of these agents in combination for superior anti-tumor activity ( Figure. 2A-B) . The potential to broaden this treatment paradigm to other histologies was confirmed by demonstrating combination therapy efficacy in the KLN205 murine lung SCC model ( Figure. 6A-B) . While the observed benefit in this model was significant, it was not as robust as seen with the RENCA model possibly due to disparities in sensitivity to reovirus oncolysis or differences in immunogenicity.
To better understand the direct cytotoxic effects of reovirus-sunitinib combination therapy on RCC, the Chou and Talalay method was utilized [23] . This line of experimentation demonstrated the potential for reovirus and sunitinib to synergistically induce cell death, highlighting enhanced direct cytotoxicity as a plausible mechanism explaining the superior therapeutic efficacy seen with these agents in combination in vivo ( Figure. 
to enhance viral replication through targeting innate immune pathways such as double stranded RNA protein Kinase R (PKR) and RNaseL, shedding light on a possible mechanism for the observed in vitro synergy [3] . Moreover, as reovirus mediated apoptosis and autophagy have previously been well characterized in other cancer cell lines and ex vivo human tumor specimens [35] [36] [37] [38] [39] , we hypothesize the observed synergy may reside in sunitinib's ability to sensitize RCC cells to these alternate modes of cell death.
In addition to direct synergistic effects on cell viability these results also support augmentation of anti-tumor immunity as a contributing mechanism mediating the observed in vivo synergy between reovirus and sunitinib. This is evidenced by a significant increase in the production of IFN-γ from tumor specific CD8 + splenocytes isolated from mice treated with reovirus-sunitinib combination therapy (Figure 3A-B) .
Augmentation of a therapeutic immune response by sunitinib is further established through our CD8 depletion ( Figure 3D-E vasculature has also been observed through intratumoral endothelial cell sensitization to oncolytic virotherapy following resolution of sunitinib therapy [41] . As such, it is likely that sunitinib and reovirus work through multiple independent mechanisms to achieve the observed in vivo synergy including both immune and non-immune mediated.
Sunitinib also has been reported to enhance therapeutic immune responses through reversing tumor induced immune suppression in patients with mRCC [3] . This activity resides partly in its ability to downregulate the levels of circulating and , or a combination of these agents. Sunitinib was given daily for 14 consecutive days starting on day 5 post RENCA implantation. Reovirus was administered three times (day 8, 11, 14) . A) Tumor size was followed with caliper measurements. N = 6 mice per group. Error bars = SEM of tumors within each group. P < 0.001 (***), 0.01 (**), 0.05 (*) by two-way ANOVA. Data representative of two independent experiments. B) KaplanMeier plot of mice treated as per panel A. N = 8 mice per group. Analysis represents data pooled from two independent experiments involving 3 and 5 mice, respectively. P < 0.001 (***) by log-rank between PBS and RV or Sunitinib + RV. P < 0.05 (*) by log-rank between RV and Sunitinib + RV. Tumor burden over time is displayed. P < 0.001 (***), by two-tailed students t-test. figure 2A . Sunitinib was given daily for 14 consecutive days starting on day 6 post KLN205 implantation. Reovirus was administered four times (day 9, 12, 15, 18) . A) Tumor size was followed with caliper measurements. N = 8 mice per group. Error bars = SEM of tumors within each group. P < 0.001 (***), 0.01 (**), 0.05 (*) by two-way ANOVA. B) Kaplan-Meier plot of mice treated as per panel A. N = 4 mice per group. P < 0.05 (*) by log-rank between PBS or RV or Sunitinib and Sunitinib + RV. C-E) Splenocytes from KLN205 tumor-bearing mice treated as per panel A (sacrificed day 23) were immunophenotyped by flow cytometry. In all panels error bars = SEM of experimental triplicate. P < 0.001 (***), 0.01 (**), 0.05 (*) by two-tailed students t-test. F) CD8 + splenocytes were isolated from KLN205 tumor-bearing mice treated as per panel A and co-cultured with KLN205 cells. % KLN205 cytotoxicity was determined by LDH assay. Error bars = SEM of experimental triplicate. P < 0.05 (*) by two-tailed students t-test.
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